.png)
Search
Selected Filter
Displaying 1–10 of 283 diseases results
-
“Asking for Help Is Not a Weakness”
Beacon StoriesAlthough signs of retinitis pigmentosa (RP) began much earlier, Marcela San Miguel Cantu wasn’t diagnosed until age 40 and only later came to fully understand how her vision was changing. Through asking for help and connecting with others, she found support, community, and hope for the future.
-
From The Life I Couldn't See Yet: A Mother, a Son, and the Future Beyond a Rare Diagnosis
Invisible DisabilityRead an excerpt from The Life I Couldn’t See Yet, where Lisa Pleasants reflects on the guilt that can come with motherhood when there is no perfect choice, from missing one of Brendon’s biggest milestones to giving him the independence he was ready for, and then getting the phone call every parent fears.
-
Beacon's emerging XLRP gene therapy improves low-light vision in phase 3 trial
Research NewsBeacon plans to begin a rolling FDA submission for laru-zova later this year
-
Nanoscope’s investigational RP treatment MOGENRY advances toward FDA approval
Research NewsOne-time injection could treat RP patients regardless of underlying genetic mutation
-
Eye on the Cure Podcast | Episode 103: Kenyetta McCurdy-Byrd and Heather Edwards
Eye on the CureTwo non-profit professionals talk about plugging into community and finding low-vision resources through the Foundation.
-
First patient treated with potential retinitis pigmentosa treatment from Sumitomo Pharma America
Research NewsCell therapy DSP-3077 is in Phase 1/2a clinical trials
-
Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment
Research NewsDeal marks another step as gildeuretinol advances towards patients
-
Jackson's New Discoveries After LUXTURNA
Beacon StoriesAfter receiving LUXTURNA at age 9, Jackson Kennedy began experiencing everyday moments he had never been able to see before—from ice cubes floating in a glass to traffic moving through a city street. Today, Jackson is an honor roll student and dedicated wrestler looking ahead to college, while embracing the possibilities his treatment has helped make possible.
-
PRIMA retinal implant restores sight in patients with geographic atrophy from AMD
Research NewsProduct launched in Europe, U.S. approval in progress
-
FDA accepts new drug application, prioritizes review for potential Stargardt treatment
Research NewsBelite Bio’s tinlarebant could become the first-ever approved treatment for Stargardt disease
